Treating type 2 diabetes patients using Boehringer Ingelheim’s oral candidate, linagliptin, leads to statistically significant and sustained reductions in blood sugar levels, according to data from four Phase III trials. The international placebo-controlled studies showed that when used as monotherapy or in combination with either metformin, pioglitazone, or metformin plus a sulfonylurea, treatment using linagliptin led to significant reductions in blood levels of hemoglobin A1c (HbA1c), fasting plasma glucose and postprandial glucose. The Phase III trial data was presented at the recent American Diabetes Association Scientific Sessions in Orlando.
Treatment using the once-daily oral drug candidate also led to improvements in beta cell function, the decline in which is believed to represent a key factor in the progression of type 2 diabetes, Boehringer Ingelheim states. Additional data from the trials showed that in patients with mild and moderate renal impairment, linagliptin blood plasma levels were comparable to those in type 2 diabetes patients with normal renal function. Boehringer Ingelheim says this finding is consistent with data suggesting linagliptin may have a primarily nonrenal route of excretion.
Linagliptin is a once-daily oral dipeptidyl peptidase-4 inhibitor designed to target the incretin hormones GLP-1 and GIP.
As the spelling of weapon is wrong I don't wish to comment. Sorry:-)
ReplyDeleteoopsss!! corrected it.
ReplyDelete